Navigation Links
Novel autoantibodies identified in patients with necrotizing myopathy
Date:8/19/2010

Researchers at Johns Hopkins University School of Medicine have identified a subgroup of patients with necrotizing myopathy who have a novel autoantibody specificity that makes them potential candidates for immunosuppressive therapy. The complete study is published in the September issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

Myopathy is a term used to describe muscle disease. The National Institute of Neurological Disorders and Stroke (NINDS) defines the inflammatory myopathies as a group of diseases that involve chronic muscle inflammation, accompanied by muscle weakness. The chronic inflammatory myopathies are idiopathic, meaning they have no known cause. They are thought to be autoimmune disorders, in which the body's white blood cells (that normally fight disease) attack blood vessels, normal muscle fibers, and connective tissue in organs, bones, and joints.

Distinguishing between immune-mediated myopathies and other necrotizing myopathies such as muscular dystrophies and self-limited toxic myopathies is crucial because only autoimmune muscle diseases respond to immunosuppressive therapy. Unfortunately, clinical evaluation and diagnostic tests sometimes fail to determine whether a necrotizing myopathy is immune mediated, resulting in undertreatment of autoimmune myopathies or inappropriate immunosuppression in patients who do not have an immune-mediated disease.

In this study, muscle biopsy specimens and serum samples were evaluated for 225 patients with myopathy who were enrolled in a longitudinal study from March 2007 through December 2008. Myopathy was defined by muscle weakness, elevated creatine kinase (CK) levels, myopathic EMG findings, muscle edema on MRI, and/or features of myopathy on muscle biopsy.

The researchers identified 26 patients with necrotizing myopathies of unclear origin. Blood samples from these patients were screened for the presence of novel autoantibodies, revealing unique autoantibody specificity against 200-kd and 100-kd proteins (anti-200/100 autoantibodies) in 16 patients. Further analysis of the clinical characteristics and muscle biopsy features of these 16 patients suggests they belong to the family of autoimmune myopathies responsive to immunosuppressive therapy.

Researchers found sera from patients with anti-200/100 autoantibodies did not recognize any of the SRP subunits, and sera from patients with anti-SRP autoantibodies did not recognize proteins with molecular weights of 200-kd or 100-kd, demonstrating that patients with the anti-200/100 autoantibody specificity are immunologically distinct from patients with anti-SRP antibodies. Furthermore, researchers noted that several anti-200/100 autoantibodypositive patients had extremely high CK levels with minimal weakness, while patients with anti-SRP antibodies and similarly high CK levels are typically very weak, suggesting the sub-group represents a unique autoimmune-based disease.

Another unique feature of the anti-200/100 autoantibodypositive group is that 63% of them underwent statin therapy prior to the development of muscle symptoms. This association was strongest in older patients; almost 90% of anti-200/100 autoantibodypositive patients ages 50 years or older had been exposed to statins. This rate was significantly higher than the rates of statin treatment in age-matched groups of patients with PM, DM, or IBM.

"We have identified a group of patients with a necrotizing myopathy and a novel anti-200/100 autoantibody specificity," said Dr. Andrew Mammen, M.D., Ph.D., and lead author of the study. "All of the patients responded to immunosuppression, and many experienced a flare of weakness when this treatment was tapered, which supports our hypothesis that this is an immune-mediated myopathy." Researchers concluded that patients with necrotizing myopathies and anti-200/100 autoantibodies most likely have an autoimmune disease and should be considered for treatment with immunosuppressive medication.


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Novel role: EZH2 boosts creation of ovarian cancer blood vessels
2. FSU study takes novel approach to understanding pituitary function
3. OU researcher developing novel therapy for Alzheimers disease
4. Vitamin B3 as a novel approach to treat fungal infections
5. Announcing: Intrinsic Imaging : Radiology Experts Launch Novel Medical Imaging CRO for Clinical Trials
6. Novel approaches to R&D in Africa needed
7. Novel radiotracer shines new light on the brains of Alzheimers disease patients
8. Team led by LA BioMed scientist develops novel approach to study neurological disorders
9. Novel paclitaxel formulation encouraging for treating advanced lung cancer
10. Novel Drug Combats Advanced Melanoma
11. Novel RNA interference screening technique identifies possible path for malignant glioma treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , ... December 06, 2016 , ... ... organization, is proud to announce it has added CXC Solutions (CXC) as a ... solutions. These solutions are tailored to help benefits advisors reduce operating costs ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... one-stop portal for all the knowledge resources, including white papers, guides, handbooks, case ... more. , To access more than 9,000 documents, webinars and videos available ...
(Date:12/6/2016)... ... December 06, 2016 , ... “Tatiana ... a powerful woman's story of sacrifice and enlightenment. , “Tatiana Sibirskaya: ... Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward writing through the ...
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates ... Top 125 for their industry leading training methods that engage their associates and ... among the global elite in employer-sponsored training and development programs. , “The 2017 ...
(Date:12/5/2016)... (PRWEB) , ... December 06, 2016 , ... For many ... Lithuanian poetry , both thick and thin. The beauty of the Lithuanian language ... Trafford Publishing). , In this poetry book, Zubinas lyrically explores all aspects of a ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016 /PRNewswire/ - InMed Pharmaceuticals, Inc. ... on its R&D program in the use of ... disease (COPD). In June, 2015 InMed initiated its ... identify the targets and potential active compounds that ... Subsequently, with in vitro assays using human lung ...
(Date:12/5/2016)... -- Balloon catheter is an innovative medical device that comprises ... artery in the leg or sometimes into the radial ... These products are generally used to prevent blood vessel ... substances in the blood vessel. In terms of revenue, ... at a CAGR of 3.8% during the forecast period ...
(Date:12/5/2016)... 5, 2016 Spain Glaucoma Surgery Devices Market ... "Spain Glaucoma Surgery Devices Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segements - Canaloplasty Micro Catheters and Glaucoma Drainage ... distribution shares data for each of these market segements, ...
Breaking Medicine Technology: